Sarepta Therapeutics
SRPT
186 hedge funds and large institutions have $2.59B invested in Sarepta Therapeutics in 2016 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 54 increasing their positions, 52 reducing their positions, and 24 closing their positions.
292% more capital invested
Capital invested by funds: $661M → $2.59B (+$1.93B)
267% more funds holding in top 10
Funds holding in top 10: 3 → 11 (+8)
158% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 24
26% more funds holding
Funds holding: 148 → 186 (+38)
4% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 52
33% less call options, than puts
Call options by funds: $524M | Put options by funds: $780M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
+$51.8M |
| 2 |
JG
Jefferies Group
New York
|
+$49.3M |
| 3 |
Millennium Management
New York
|
+$48.7M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$21.1M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$17.3M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.7M |
| 3 |
Morgan Stanley
New York
|
-$14.6M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$12.2M |
| 5 |
PA
Perceptive Advisors
New York
|
-$11.2M |
SRPT Hedge Fund Activity: Q3 2016 in Review
186 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2016, worth a combined $2.59B — up 292% from $661M a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new SRPT positions and 24 closed out — a net gain of 38 holders — while 54 added to existing stakes and 52 trimmed.
The largest buyer was Tourbillon Capital Partners, opening a new position worth an estimated $51.8M. The largest seller was Group One Trading, exiting entirely with an estimated $17.3M sold.
- 186 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2016, up from 148 in Q2 2016.
- Funds reported $2.59B of Sarepta Therapeutics stock for Q3 2016, up 292% quarter-over-quarter.
- 62 funds opened new Sarepta Therapeutics positions in Q3 2016 and 24 closed out, a net change of +38 holders.
- The largest Sarepta Therapeutics buyer in Q3 2016 was Tourbillon Capital Partners, an estimated $51.8M added.
- The largest Sarepta Therapeutics seller in Q3 2016 was Group One Trading, an estimated $17.3M sold.
Based on aggregated 13F filings for Q3 2016.